These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 33272690

  • 21. Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
    Carosio R, Fontana V, Mastracci L, Ferro P, Grillo F, Banelli B, Canessa PA, Dessanti P, Vigani A, Morabito A, Pfeffer U, Poggi A, Roncella S, Pistillo MP.
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):459-468. PubMed ID: 33216211
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    Hsu PC, Miao J, Wang YC, Zhang WQ, Yang YL, Wang CW, Yang CT, Huang Z, You J, Xu Z, Jablons DM, You L.
    J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
    [Abstract] [Full Text] [Related]

  • 23. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [Abstract] [Full Text] [Related]

  • 24. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M.
    Hum Pathol; 2018 Jan; 71():1-7. PubMed ID: 28811252
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
    Pezzuto F, Vimercati L, Fortarezza F, Marzullo A, Pennella A, Cavone D, Punzi A, Caporusso C, d'Amati A, Lettini T, Serio G.
    Diagn Pathol; 2021 Jul 22; 16(1):64. PubMed ID: 34294087
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
    Arimura K, Hiroshima K, Nagashima Y, Nakazawa T, Ogihara A, Orimo M, Sato Y, Katsura H, Kanzaki M, Kondo M, Tagaya E.
    BMC Cancer; 2023 Dec 07; 23(1):1206. PubMed ID: 38062416
    [Abstract] [Full Text] [Related]

  • 29. A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
    Passiglia F, Bironzo P, Righi L, Listì A, Arizio F, Novello S, Volante M, Scagliotti GV.
    Clin Lung Cancer; 2021 Jan 07; 22(1):e63-e66. PubMed ID: 32917522
    [Abstract] [Full Text] [Related]

  • 30. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
    Qualiotto AN, Baldavira CM, Balancin M, Ab'Saber A, Takagaki T, Capelozzi VL.
    Front Immunol; 2023 Jan 07; 14():1268927. PubMed ID: 37901248
    [Abstract] [Full Text] [Related]

  • 31. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
    Mansour MSI, Seidal T, Mager U, Baigi A, Dobra K, Dejmek A.
    Cancer Cytopathol; 2017 Dec 07; 125(12):908-917. PubMed ID: 28922567
    [Abstract] [Full Text] [Related]

  • 32. Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma.
    Mansour MSI, Seidal T, Mager U, Dobra K, Brunnström H, Dejmek A.
    Cancer Cytopathol; 2021 Jun 07; 129(6):468-478. PubMed ID: 33493383
    [Abstract] [Full Text] [Related]

  • 33. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
    Cho H, Matsumoto S, Fujita Y, Kuroda A, Menju T, Sonobe M, Kondo N, Torii I, Nakano T, Lara PN, Gandara DR, Date H, Hasegawa S.
    J Thorac Oncol; 2017 Mar 07; 12(3):477-490. PubMed ID: 27867002
    [Abstract] [Full Text] [Related]

  • 34. Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
    Ghanim B, Rosenmayr A, Stockhammer P, Vogl M, Celik A, Bas A, Kurul IC, Akyurek N, Varga A, Plönes T, Bankfalvi A, Hager T, Schuler M, Hackner K, Errhalt P, Scheed A, Seebacher G, Hegedus B, Stubenberger E, Aigner C.
    Sci Rep; 2020 Apr 01; 10(1):5784. PubMed ID: 32238865
    [Abstract] [Full Text] [Related]

  • 35. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness.
    Inaguma S, Lasota J, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Schrump DS, Hassan R, Kasai K, Miettinen M, Ikeda H.
    J Pathol; 2020 Feb 01; 250(2):205-216. PubMed ID: 31639216
    [Abstract] [Full Text] [Related]

  • 36. Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients.
    Fusco N, Vaira V, Righi I, Sajjadi E, Venetis K, Lopez G, Cattaneo M, Castellani M, Rosso L, Nosotti M, Clerici M, Ferrero S.
    Lung Cancer; 2020 Dec 01; 150():53-61. PubMed ID: 33065463
    [Abstract] [Full Text] [Related]

  • 37. Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland.
    Vizcaya D, Farahmand B, Walter AO, Kneip C, Jöhrens K, Tukiainen M, Schmitz AA.
    Cancer Treat Res Commun; 2020 Dec 01; 25():100260. PubMed ID: 33310366
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma.
    Rrapaj E, Trisolini E, Bertero L, Salvo M, Indellicato R, Andorno S, Garcia-Manteiga JM, Rena O, Boldorini RL.
    Histopathology; 2018 May 01; 72(6):1039-1050. PubMed ID: 29356044
    [Abstract] [Full Text] [Related]

  • 40. Preoperative neutrophil-to-lymphocyte ratio correlates with PD-L1 expression in immune cells of patients with malignant pleural mesothelioma and predicts prognosis.
    Okita R, Kawamoto N, Okada M, Inokawa H, Yamamoto N, Murakami T, Ikeda E.
    Sci Rep; 2023 Mar 31; 13(1):5263. PubMed ID: 37002247
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.